At #HFSA2025, we spoke with Milind Desai, MD, to discuss recent advancements in hypertrophic cardiomyopathy diagnosis, treatment, and management.
Watch now: www.hcplive.com/view/the-evo...
0
0
0
0
Hashtag
#HFSA2025
Advertisement · 728 × 90
"A lot of us come out trained and behave kind of in a more homogeneous way. I don't know that's a good sign for things to come in the field." -- @eirangorodeski.bsky.social, discussing a weakness of advanced heart failure/transplant cardiology training. #HFSA2025
www.medpagetoday.com/meetingcover...
1
0
1
0
Disappointingly, a growth differentiation factor 15 neutralizer not only failed to improve functional outcomes in heart failure but was associated with harm in a trial that was terminated early. #HFSA2025
www.medpagetoday.com/meetingcoverage/hfsa/117...
0
0
0
0
“The time-sensitive nature of transthyretin cardiomyopathy is something that has been on many people’s minds, but I think this is the first piece of evidence that should push us forward,” said Ahmad Masri, MD at #HFSA2025. #CardioSky
2
1
1
0
People with heart failure may have congestion events detected early using a speech processing app on their smartphone, according to preliminary training data from HearO technology. #HFSA2025
www.medpagetoday.com/meetingcoverage/hfsa/117...
1
0
0
0
“You often learn from when science goes the opposite direction from what you expect,” said presenter David Berg, MD. The next question to answer is what role GDF-15 plays in heart failure. #HFSA2025 #CardioSky
1
2
0
0
The small-molecule drug candidate danicamtiv showed promise for activating myosin in gene-related dilated cardiomyopathy, based on a small phase IIa study. #HFSA2025
www.medpagetoday.com/meetingcoverage/hfsa/117...
0
0
0
0
How can advanced heart failure care persevere in the face of dwindling interest and stagnation? The field is already in dire straits, some say, while the field mostly sits on expert calls to overhaul training and renumeration. #HFSA2025
www.medpagetoday.com/meetingcoverage/hfsa/117...
0
0
0
0
The novel dual-function cardiac contractility modulation-defibrillator for heart failure with reduced ejection fraction had favorable early results in the Integra-D trial. #HFSA2025
www.medpagetoday.com/meetingcoverage/hfsa/117...
0
0
0
0
Another from #HFSA2025: this time looking at a new CCM-D device in patients with HFrEF. Will this be enough for CCM to gain traction in the HF world? #CardioSky
0
2
0
0
My first from #HFSA2025 and an interesting one to boot! The Cordio HearO App can pick up signals of heart failure events more than 3 weeks before they happen. #CardioSky
0
2
0
0
0
0
0
0
We presented exploratory data from ATTRibute-CM looking at all events - CVM and recurrent CVH - which show early and sustained effect of acoramidis throughout the study.
#HFSA2025
#MedIQHFSA2025
0
0
1
0
Ronald Witteles, MD presented on outcomes of vutrisiran monotherapy (vs placebo) in HELIOS-B with and without censoring tafamidis drop ins
#HFSA2025
#MedIQHFSA2025
0
0
1
0
Emily Martin presented on correlation of Tc-99m p5+14 in cardiac amyloidosis with clinical markers
#HFSA2025
#MedIQHFSA2025
0
0
1
0
Continues acoramidis reduced ACM/CVH from the parent study to the OLE portion at Month 42
#HFSA2025
#MedIQHFSA2025
0
0
1
0
Data from ATTRibute-CM on acoramidis potentially preventing the progression of conduction disease as part of ATTR-CM presented at #HFSA2025
#MedIQHFSA2025
0
0
1
0
Data from ATTRibute-CM on the NTproBNP response in the subgroup of variant ATTR patients. Acoramidis mitigated the rise of NTproBNP as compared to placebo
#HFSA2025
#MedIQHFSA2025
0
0
1
0
Large dataset on V122I both homozygous and heterozygous from the VA presented at #HFSA2025
#MedIQHFSA2025
1
0
1
0
Efficacy of vutrisiran in HELIOS-B by baseline health status (KCCQ) - consistent effects across the different categories analyzed
#HFSA2025
#MedIQHFSA2025
0
0
1
0
Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025.
Check out this thread for highlights.
#MedIQHFSA2025
1
0
1
0
Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was generally well tolerated in participants with #DCM https://bit.ly/4mE3vcM
#HFSA2025 #JACC #cvGenetics @jimjanuzzi.bsky.social
4
3
0
0
🚨Our final #HFSA2025 Simpub! In this 🔥ECT Spotlight, @vbluml describes the critical distinction between native 🫀 survival, remission & recovery in CS, underscoring the implications of precise terminology for clinical care, research, and systems of care.
🔗 http://bit.ly/4mGN67A
1
0
0
0
As the @hfsa.bsky.social Annual Scientific Meeting 2025 comes to a close, here are the final #HFSA2025 SimPubs, out now in the Journal of Cardiac Failure. 🚨
🧵👇
1
0
1
0
🚨 A big day of #HFSA2025 SimPubs! 7 new articles will be published today, simultaneous with the #HFSA2025 @hfsa.bsky.social
Check out the first three, out now in the Journal of Cardiac Failiure
🧵
1
0
1
0
Acoramidis 📉 cumulative CV outcomes in #ATTRCM vs placebo, w/ numerical differences by month 1 & 📈 through month 30 (53 events avoided/100 pts). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely Tx https://bit.ly/4gLv5DG
#HFSA2025 #JACC #CardioSky
4
3
1
0
🚨More #HFSA2025 sim pubs out today @Jcardfail! 🚨
Hemodynamics and crosstalk between HF & EP! 📃🫀
2
2
2
0
The first plenary session at #HFSA2025 is about to begin and all of my coverage will be on @tctmd.bsky.social! Who else is here and what are you looking forward to at the meeting?
1
0
0
0
🚨 #HFSA2025 SimPub alert!
The Heart Failure Society America’s 2025 Annual Scientific Meeting kicks off today, and JCF has 12 simultaneous publications releasing during the meeting!
1
2
2
0
Between 2021-2025, relatively few AHFTC fellowship programs matched most applicants. Applicants prioritize markers of hospital reputation & #Hearttx volumes over regional disease burden or geographical considerations. https://bit.ly/4nHnWXP
#HFSA2025 #JACCHF #ACCHFT @eirangorodeski.bsky.social
2
3
0
0